III期-话题@MedSci

#III期#

681篇内容 | 2788人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594567, encodeId=6c10159456ea6, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据, objectType=article, longId=160662, objectId=4eb716066282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb716066282, replyNumber=0, likeNumber=67, createdTime=2019-02-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb716066282, moduleTitle=辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb716066282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594566, encodeId=2199159456650, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, objectType=article, longId=160650, objectId=909e1606500c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909e1606500c, replyNumber=0, likeNumber=0, createdTime=2019-02-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909e1606500c, moduleTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909e1606500c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594565, encodeId=5c911594565e7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, objectType=article, longId=160563, objectId=3f571605635b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f571605635b, replyNumber=0, likeNumber=68, createdTime=2019-02-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f571605635b, moduleTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f571605635b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594564, encodeId=e7481594564f5, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, objectType=article, longId=160546, objectId=fa9316054665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9316054665, replyNumber=0, likeNumber=89, createdTime=2019-02-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9316054665, moduleTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9316054665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594563, encodeId=46881594563bc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, objectType=article, longId=160438, objectId=5b3116043863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3116043863, replyNumber=0, likeNumber=136, createdTime=2019-02-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3116043863, moduleTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3116043863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594562, encodeId=c18615945626b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, objectType=article, longId=160425, objectId=2800160425be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2800160425be, replyNumber=0, likeNumber=94, createdTime=2019-02-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2800160425be, moduleTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2800160425be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594561, encodeId=358d159456140, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, objectType=article, longId=160421, objectId=524e160421b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=524e160421b4, replyNumber=0, likeNumber=49, createdTime=2019-02-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=524e160421b4, moduleTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=524e160421b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594560, encodeId=fb9f159456007, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, objectType=article, longId=160414, objectId=ea1416041497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1416041497, replyNumber=0, likeNumber=21, createdTime=2019-02-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1416041497, moduleTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1416041497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594559, encodeId=87c71594559d7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, objectType=article, longId=160342, objectId=a54e16034284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a54e16034284, replyNumber=0, likeNumber=67, createdTime=2019-02-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a54e16034284, moduleTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a54e16034284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594558, encodeId=6fb8159455809, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet Gastroen Hepatol：慢性丙型肝炎抗病毒新药临床III期试验研究进展, objectType=article, longId=159965, objectId=41ba15996571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ba15996571, replyNumber=0, likeNumber=25, createdTime=2019-02-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ba15996571, moduleTitle=Lancet Gastroen Hepatol：慢性丙型肝炎抗病毒新药临床III期试验研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ba15996571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594557, encodeId=7abf159455e38, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Theravance Biopharma宣布Ampreloxetine III期研究治疗症状性神经源性直立性低血压患者入组, objectType=article, longId=159219, objectId=850a159219d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=850a159219d1, replyNumber=0, likeNumber=27, createdTime=2019-01-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=850a159219d1, moduleTitle=Theravance Biopharma宣布Ampreloxetine III期研究治疗症状性神经源性直立性低血压患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=850a159219d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594556, encodeId=45f01594556f2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Bardoxolone治疗常染色体显性多囊肾病的III期试验正式开始, objectType=article, longId=159160, objectId=1493159160dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1493159160dd, replyNumber=0, likeNumber=81, createdTime=2019-01-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1493159160dd, moduleTitle=Bardoxolone治疗常染色体显性多囊肾病的III期试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1493159160dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594555, encodeId=218c159455529, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, objectType=article, longId=158889, objectId=58081588897d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58081588897d, replyNumber=0, likeNumber=59, createdTime=2019-01-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58081588897d, moduleTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58081588897d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594554, encodeId=263d159455457, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, objectType=article, longId=158309, objectId=2e6815830948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6815830948, replyNumber=0, likeNumber=68, createdTime=2019-01-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6815830948, moduleTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6815830948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594553, encodeId=8d4a159455356, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Amryt 制药公布 III期 EASE试验的疗效分析结果, objectType=article, longId=157474, objectId=f44e15e4740c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f44e15e4740c, replyNumber=0, likeNumber=67, createdTime=2019-01-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f44e15e4740c, moduleTitle=Amryt 制药公布 III期 EASE试验的疗效分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f44e15e4740c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594552, encodeId=150115945526f, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Gastroenterology：肿瘤部位对III期结肠癌淋巴结数量的影响与预后的关系, objectType=article, longId=157443, objectId=39a215e443c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39a215e443c7, replyNumber=0, likeNumber=70, createdTime=2019-01-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39a215e443c7, moduleTitle=J Gastroenterology：肿瘤部位对III期结肠癌淋巴结数量的影响与预后的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39a215e443c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594551, encodeId=45801594551bf, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=II期j临床试验成功而III期临床失败的案例教训, objectType=article, longId=157416, objectId=f2d315e41677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2d315e41677, replyNumber=0, likeNumber=67, createdTime=2019-01-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2d315e41677, moduleTitle=II期j临床试验成功而III期临床失败的案例教训, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2d315e41677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594550, encodeId=ec36159455092, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Incyte宣布开展Ruxolitinib的III期临床试验, objectType=article, longId=156672, objectId=aeee1566e228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeee1566e228, replyNumber=0, likeNumber=71, createdTime=2018-12-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeee1566e228, moduleTitle=Incyte宣布开展Ruxolitinib的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeee1566e228)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594549, encodeId=509b159454922, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果, objectType=article, longId=156671, objectId=78e61566e182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78e61566e182, replyNumber=0, likeNumber=76, createdTime=2018-12-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78e61566e182, moduleTitle=XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78e61566e182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594548, encodeId=314e1594548dd, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, objectType=article, longId=156456, objectId=54b315645636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b315645636, replyNumber=0, likeNumber=27, createdTime=2018-12-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b315645636, moduleTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54b315645636)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据

2019-02-22

智智灵药 (审核中...)

前往app查看评论内容

#III期#

默克Keytruda治疗晚期肝癌的III期临床试验失败告终

2019-02-22

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案

2019-02-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率

2019-02-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验

2019-02-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据

2019-02-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验

2019-02-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率

2019-02-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始

2019-02-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet Gastroen Hepatol：慢性丙型肝炎抗病毒新药临床III期试验研究进展

2019-02-15

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Theravance Biopharma宣布Ampreloxetine III期研究治疗症状性神经源性直立性低血压患者入组

2019-01-31

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Bardoxolone治疗常染色体显性多囊肾病的III期试验正式开始

2019-01-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验

2019-01-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药

2019-01-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Amryt 制药公布 III期 EASE试验的疗效分析结果

2019-01-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Gastroenterology：肿瘤部位对III期结肠癌淋巴结数量的影响与预后的关系

2019-01-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

II期j临床试验成功而III期临床失败的案例教训

2019-01-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Incyte宣布开展Ruxolitinib的III期临床试验

2018-12-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果

2018-12-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

"PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开

2018-12-24

科室
- - 订阅+
  - 更多科室
工具
服务